Genelux Corporation is a biopharmaceutical company based in Redlands, CA, that is dedicated to developing innovative therapeutics to address unmet medical needs in the field of immuno-oncology. Their proprietary discovery platform, CHOICE, allows them to rapidly generate new product candidates for the treatment of various cancers, including platinum-resistant refractory ovarian cancer and recurrent non-small cell lung cancer.
Utilizing the vaccinia virus as the backbone of their therapeutics and diagnostics platform, Genelux aims to re-sensitize resistant tumors to chemotherapy and establish long-term antitumor immunity. Their lead clinical candidate, Olvi-Vec, has demonstrated promising antitumor activity as monotherapy and combination therapy, and has the potential to be a versatile and personalized treatment option for a range of difficult-to-treat cancers.
Generated from the website
